← Back to Screener
Amgen Inc (AMGN)
Price$349.58
Value ScoreC
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-6.73%
Price vs S&P 500 (4W)5.40%
VGM Score49.94
Market Capitalization$188.67B
P/E Ratio (Annual)24.47x
Indicated Dividend Yield (Annual)2.92%
All Metrics
P/CF (Annual)18.95x
Book Value / Share (Quarterly)$17.02
P/TBV (Annual)24.53x
Indicated Dividend (Annual)$10.08
Revenue Growth (3Y)11.77%
Cash Flow / Share (Quarterly)$15.92
Payout Ratio (TTM)66.45%
Price vs S&P 500 (YTD)-1.35%
Gross Margin (TTM)73.95%
Net Profit Margin (TTM)20.96%
EPS (TTM)$14.38
10-Day Avg Trading Volume2.28M
EPS Excl Extra (TTM)$14.38
Revenue Growth (5Y)7.65%
EPS (Annual)$14.23
Dividend / Share (Annual)$9.53
ROI (Annual)12.19%
Gross Margin (Annual)70.78%
Net Profit Margin (5Y Avg)20.92%
Cash / Share (Quarterly)$22.29
P/E Basic Excl Extra (TTM)24.19x
Revenue Growth QoQ (YoY)5.76%
EPS Growth (5Y)2.93%
P/E Normalized (Annual)24.47x
ROA (Last FY)8.51%
Revenue Growth TTM (YoY)9.07%
EBITD / Share (TTM)$26.74
ROE (5Y Avg)106.67%
Operating Margin (TTM)28.80%
Cash Flow / Share (Annual)$15.03
P/B Ratio20.53x
P/B Ratio (Quarterly)20.66x
Net Income / Employee (Annual)$244,800
EV / Revenue (TTM)6.29x
Net Interest Coverage (TTM)12.70x
ROA (TTM)8.64%
EPS Growth QoQ (YoY)4.57%
EV / EBITDA (TTM)16.13x
EPS Incl Extra (Annual)$14.23
Current Ratio (Annual)1.14x
Quick Ratio (Quarterly)1.01x
3-Month Avg Trading Volume2.70M
52-Week Price Return21.76%
EV / Free Cash Flow (Annual)28.88x
P/E Incl Extra (TTM)24.19x
Revenue / Employee (TTM)$1,181,600
Tangible BV / Share (Quarterly)$7.09
P/S Ratio (Annual)5.13x
Asset Turnover (Annual)0.41x
52-Week High$391.29
Operating Margin (5Y Avg)28.53%
EPS Excl Extra (Annual)$14.23
CapEx CAGR (5Y)25.03%
Tangible BV CAGR (5Y)-10.56%
26-Week Price Return1.19%
Quick Ratio (Annual)0.78x
13-Week Price Return-4.90%
Total Debt / Equity (Annual)6.31x
Current Ratio (Quarterly)1.26x
Enterprise Value$233.96B
Revenue / Share Growth (5Y)9.49%
Asset Turnover (TTM)0.41x
Book Value / Share Growth (5Y)-0.25%
Revenue / Employee (Annual)$1,166,700
Inventory Turnover (Annual)1.62x
Pretax Margin (Annual)24.42%
Cash / Share (Annual)$16.94
3-Month Return Std Dev23.82%
Gross Margin (5Y Avg)72.09%
Net Income / Employee (TTM)$247,600
EBITDA CAGR (5Y)2.64%
EBITDA Interim CAGR (5Y)-2.14%
ROE (Last FY)89.06%
Net Interest Coverage (Annual)2.53x
EPS Basic Excl Extra (Annual)$14.23
P/FCF (TTM)21.95x
Receivables Turnover (TTM)4.31x
EV / Free Cash Flow (TTM)27.21x
Total Debt / Equity (Quarterly)6.24x
EPS Incl Extra (TTM)$14.38
Receivables Turnover (Annual)4.50x
ROI (TTM)12.11%
Dividend Growth Rate (5Y)8.21%
P/S Ratio (TTM)5.07x
Pretax Margin (5Y Avg)23.95%
Revenue / Share (Annual)$67.81
Tangible BV / Share (Annual)$8.03
Forward P/E14.75x
Free OCF CAGR (5Y)-3.91%
Price vs S&P 500 (52W)-2.60%
P/E Ratio (TTM)24.19x
EPS Growth TTM (YoY)31.27%
Year-to-Date Return6.80%
5-Day Price Return6.21%
EPS Normalized (Annual)$14.23
ROA (5Y Avg)7.91%
Net Profit Margin (Annual)20.98%
Month-to-Date Return3.80%
Cash Flow / Share (TTM)$20.77
EBITD / Share (Annual)$26.77
EPS Growth (3Y)5.51%
Operating Margin (Annual)25.43%
LT Debt / Equity (Annual)5.78x
P/CF (TTM)17.54x
ROI (5Y Avg)11.60%
P/E Excl Extra (TTM)24.19x
LT Debt / Equity (Quarterly)5.65x
EPS Basic Excl Extra (TTM)$14.38
P/TBV (Quarterly)27.47x
Payout Ratio (Annual)66.45%
P/B Ratio (Annual)20.36x
Dividend / Share (TTM)$9.53
Inventory Turnover (TTM)1.50x
Pretax Margin (TTM)24.41%
Book Value / Share (Annual)$16.07
Price vs S&P 500 (13W)-13.16%
Net Margin Growth (5Y)-5.99%
Dividend Yield (TTM)2.72%
Beta0.41x
P/FCF (Annual)23.29x
Revenue / Share (TTM)$68.42
ROE (TTM)89.41%
52-Week Low$267.83
vGradeC
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 265.15est. 4.85
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.55
3.53
3.52
3.55
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $71.53 |
About
Amgen is a leading global biotechnology company with a diversified portfolio spanning oncology, cardiovascular disease, immunology, inflammation, and rare diseases. The company has expanded through strategic acquisitions including Onyx Pharmaceuticals and Horizon Therapeutics, while building a growing biosimilar business alongside marketed drugs across multiple therapeutic franchises. Recent launches demonstrate continued innovation in areas including cardiovascular health, migraine, oncology, and immunology.